NewsBenzingaFoghorn Therapeutics riorienta la pipeline dopo la fine dell'accordo con Eli Lilly Foghorn Therapeutics riorienta la pipeline dopo la fine dell'accordo con Eli Lilly Benzinga 2026.10.01 16:17 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Equal-Weight on Commercial Metals, Lowers Price Target to $63 Dow Falls Over 300 Points; Nvidia Posts Upbeat Earnings TD Cowen Maintains Hold on Calumet, Lowers Price Target to $37 If You Invested $100 In Cenovus Energy Stock 5 Years Ago, You Would Have This Much Today Wells Fargo Maintains Overweight on Cleveland-Cliffs, Raises Price Target to $18 TD Cowen Maintains Buy on BWX Technologies, Lowers Price Target to $180